The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA2003; 289: 2560–72.
2.
BerlowitzDRAshASHickeyECFriedmanRHGlickmanMKaderB, Inadequate management of blood pressure in a hypertensive population. N Engl J Med1998; 339: 1957–63.
3.
HymanDJPavlikVN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med2001; 345: 479–86.
4.
OliveriaSALapuertaPMcCarthyBDL'ItalienGJBerlowitzDRAschSM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med2002; 162: 413–20.
5.
ChabotIMoisanJGrégoireJ-PMilotA. Pharmacist intervention program for control of hypertension. Ann Pharmacother2003; 37: 1186–93. DOI 10.1345/aph.1C267
6.
CarterBLZillichAJElliottWJ. How pharmacists can assist physicians with controlling blood pressure. J Clin Hypertens2003; 5: 31–7.
7.
CarterBLBarnetteDJChrischillesEMazzottiGJAsaliZJ. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy1997; 17: 1274–85.
8.
McKenneyJMSliningJMHendersonHRDevinsDBarrM. The effect of clinical pharmacy services on patients with essential hypertension. Circulation1973; 48: 1104–11.
9.
EricksonSRSlaughterRHalapyH. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy1997; 17: 140–7.
10.
BondCAMonsonR. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med1984; 144: 1159–62.
11.
BorensteinJEGraberGSaltielEWallaceJRyuSArchiJ, Physician–pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy2003; 23: 209–16.
12.
MehosBMSaseenJJMacLaughlinEJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy2000; 20: 1384–9.
13.
KennieNRSchusterBGEinarsonTR. Critical analysis of the pharmaceutical care research literature. Ann Pharmacother1998; 32: 17–26. Erratum 1998; 32: 612.
14.
SinghalPKRaischDWGupchupGV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother1999; 33: 1336–55.
15.
MaloneDCCarterBLBillupsSJValuckRJBarnetteDJSintekCD, An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy2000; 20: 1149–58.
16.
WeinbergerMMurrayMDMarreroDGBrewerNLykensMHarrisLE, Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA2002; 288: 1594–602.
17.
CarterBLChrischillesEAScholzDHayaseNBellN. Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program. J Am Pharm Assoc2003; 43: 24–33.
18.
RouxA DiezChamblessLMerkinSSArnettDEigenbrodtMNietoFJ, Socioeconomic disadvantage and change in blood pressure associated with aging. Circulation2002; 106: 703–10.
19.
AngristJDImbensGWRubinDB. Identification of causal effects using instrumental variables. J Am Statistical Assoc1996; 91: 444–54.
20.
BalkeAPearlJ. Bounds of treatment effects from studies with imperfect compliance. J Am Statistical Assoc1997; 92: 1171–6.
21.
GreenlandS. An introduction to instrumental variables for epidemiologists. Int J Epidemiol2000; 29: 722–9.
